Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Black Diamond Therapeutics (BDTX)
NASDAQ:BDTX
RESEARCH TOOLSreports
Black Diamond Therapeutics (BDTX) Stock Price & Analysis
746 Followers
BDTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.62 - $7.66
Previous Close$5.75
Volume368.43K
Average Volume (3M)786.50K
Market Cap
$323.45M
Enterprise Value$229.62M
Total Cash (Recent Filing)$115.20M
Total Debt (Recent Filing)$21.36M
Price to Earnings (P/E)―
Beta3.68
Next Earnings
Aug 08, 2024EPS Estimate
-$0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.70
Shares Outstanding56,252,794
10 Day Avg. Volume713,902
30 Day Avg. Volume786,504
Standard Deviation0.35
R-Squared0.16
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)2.61
Price to Sales (P/S)271.45
Price to Cash Flow (P/CF)-3.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue157.38
Enterprise Value/Gross Profit201.77
Enterprise Value/Ebitda-2.89
Forecast
1Y Price Target
$12.67Price Target Upside120.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Black Diamond Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsBDTX-1535 continues to show promise in brain cancer, with eight of nine patients exceeding the PK threshold of 4.1nM unbound drug concentration.
Financial PerformanceBlack Diamond reported a net loss of $0.35 per share, which is narrower than the prior estimated net loss of $0.44 per share.
Market PotentialSuccess in both GBM and Tagrisso-resistant NSCLC could support peak global sales of over $1 billion.
Bears Say
Analyst SentimentAnalysts are cautious in ascribing value to BDTX-1535 in brain cancer due to historical challenges and the need for combination regimens to overcome resistance.
Clinical DataIt is unclear what percentage of patients experienced loss of EGFR mutations.
Treatment StrategiesConcomitant activation of multiple redundant receptor tyrosine kinases may require combination regimens.
---
Ownership Overview
58.66% Insiders
11.48% Mutual Funds
7.69% Other Institutional Investors
22.18% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
BDTX FAQ
What was Black Diamond Therapeutics’s price range in the past 12 months?
Black Diamond Therapeutics lowest stock price was $1.62 and its highest was $7.66 in the past 12 months.
What is Black Diamond Therapeutics’s market cap?
Currently, no data Available
When is Black Diamond Therapeutics’s upcoming earnings report date?
Black Diamond Therapeutics’s upcoming earnings report date is Aug 08, 2024 which is in 17 days.
How were Black Diamond Therapeutics’s earnings last quarter?
Black Diamond Therapeutics released its earnings results on May 09, 2024. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.434 by $0.084.
Is Black Diamond Therapeutics overvalued?
According to Wall Street analysts Black Diamond Therapeutics’s price is currently Undervalued.
Does Black Diamond Therapeutics pay dividends?
Black Diamond Therapeutics does not currently pay dividends.
What is Black Diamond Therapeutics’s EPS estimate?
Black Diamond Therapeutics’s EPS estimate is -$0.39.
How many shares outstanding does Black Diamond Therapeutics have?
Black Diamond Therapeutics has 56,252,792 shares outstanding.
What happened to Black Diamond Therapeutics’s price movement after its last earnings report?
Black Diamond Therapeutics reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.434. Following the earnings report the stock price went down -2.738%.
Which hedge fund is a major shareholder of Black Diamond Therapeutics?
Among the largest hedge funds holding Black Diamond Therapeutics’s share is RA Capital Management. It holds Black Diamond Therapeutics’s shares valued at 18M.
---
Black Diamond Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.67 (120.35% Upside)
$12.67 (120.35% Upside)
Blogger Sentiment
Bullish
BDTX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 176.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.9%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.29%
12-Months-Change
Fundamentals
Return on Equity
-78.81%
Trailing 12-Months
Asset Growth
5.12%
Trailing 12-Months
Company Description
Black Diamond Therapeutics
Black Diamond Therapeutics, Inc. engages in the biotechnology company that discovers and develops therapeutic agents to target unique oncogenic protein-isoforms. The company was founded by Dr. David M. Epstein and Dr. Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.
---
BDTX Stock 12 Month Forecast
Average Price Target
$12.67
▲(120.35% Upside)
Technical Analysis
Best Analysts Covering BDTX
1 Year
1 Year Success Rate
7/11 ratings generated profit
1 Year Average Return
+32.49%
reiterated a buy rating 2 months ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +32.49% per trade.
---